SEARCH

SEARCH BY CITATION

References

  • 1
    Global burden of disease (GBD) for hepatitis C. Global Burden Of Hepatitis C Working Group. J Clin Pharmacol 2004; 44: 20-29.
  • 2
    Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. European Centre for Disease Prevention and Control, September 2010.
  • 3
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
  • 4
    Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. HEPATOLOGY 2004; 39: 333-342.
  • 5
    Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. HEPATOLOGY 2010; 51: 2069-2076.
  • 6
    Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
  • 7
    Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288.
  • 8
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
  • 9
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 17; 461: 399-401.
  • 10
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.e18.
  • 11
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 12
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 13
    Ghany M, Nelson D, Strader D, Thomas D, Seeff LB. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. HEPATOLOGY 2011; 54: 1433-1444.
  • 14
    Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? HEPATOLOGY 2011; 53: 1789-1791.
  • 15
    Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 25-31.
  • 16
    National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 2010. Peginterferon alfa and ribavirin treatment of chronic hepatitis C. Issue date: September 2010.
  • 17
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
  • 18
    FDA Antiviral Drugs Advisory Committee Meeting. Boceprevir. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM254079.pdf. Accessed August 3, 2011.
  • 19
    Victrelis [boceprevir]. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002332/human_med_001464.jsp. Accessed August 17, 2011.
  • 20
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 21
  • 22
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  • 23
    Drummond AJ, Ho SY, Phillips MJ, Rambaut A. Relaxed phylogenetics and dating with confidence. PLoS Biol 2006; 4: e88.
  • 24
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001; 34: 809-816.
  • 25
    Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75.
  • 26
    Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, et al. Liver Match Investigators. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155-164.
  • 27
    Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700.
  • 28
    Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110-115.
  • 29
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
  • 30
    Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432.
  • 31
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
  • 32
    R Development Core Team ( 2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
  • 33
    ISTAT, http://www.istat.it/prezzi/precon/dati/ Last accessed, February 2011.
  • 34
    Wolters Kluwer Health. Medi-Span Master Drug Data Base v2.5 (MDDB). Accessed September 20, 2011.
  • 35
    Munari L, Picciotto A. Recombinant interferon alfa-2b therapy for chronic hepatitis C in Italy: an economic analysis. FORUM Trends Exp Clin Med 1996; 6: 347-353.
  • 36
    Conferenza delle Regioni e Provincie Autonome. Tariffa Unica Concenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per il 2006. Rome, 15 December 2005.
  • 37
    Sullivan SD, Craxì A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. Pharmacoeconomics 2004; 22: 257-265.
  • 38
    Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22( Suppl 4): 5-10.
  • 39
    Callahan D. Health Technology Assessment Implementation: The Politics of Ethics. Med Decis Making 2012; 32: E13-E19.